Jane Street Group, LLC Altimmune, Inc. Call Options Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $221,100 - $325,620	40,200 New	40,200 $246,000
Q1 2022 May 17, 2022	SELL	$5.9 - $9.45 $396,480 - $635,040	-67,200 Reduced 74.34%	23,200 $141,000
Q4 2021 Feb 15, 2022	SELL	$8.69 - $12.48 $868,131 - $1.25 Million	-99,900 Reduced 52.5%	90,400 $828,000
Q3 2021 Nov 16, 2021	BUY	$8.43 - $16.81 $660,912 - $1.32 Million	78,400 Added 70.06%	190,300 $2.15 Million
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $66,980 - $111,928	6,800 Added 6.47%	111,900 $1.1 Million
Q1 2021 May 18, 2021	BUY	$12.71 - $24.31 $100,409 - $192,049	7,900 Added 8.13%	105,100 $1.49 Million
Q4 2020 Feb 17, 2021	BUY	$7.84 - $14.22 $94,864 - $172,062	12,100 Added 14.22%	97,200 $1.1 Million
Q3 2020 Nov 17, 2020	BUY	$9.93 - $33.26 $383,298 - $1.28 Million	38,600 Added 83.01%	85,100 $1.12 Million
Q2 2020 Aug 17, 2020	BUY	$2.9 - $10.71 $134,850 - $498,015	46,500 New	46,500 $498,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $353M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.